Management of the menopausal disturbances and oxidative stress

Current Pharmaceutical Design

Volumn 11, Issue 16, 2005, Pages 2063-2073

  Pansini, Francesco ^a   Mollica, Gioacchino ^a   Bergamini, Carlo M ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Climacteric syndrome; Hormone therapy; Menopause; Oxidative damage; Phytoestrogens; SEEM; SERM

Indexed keywords

ALENDRONIC ACID; ALPHA ADRENERGIC RECEPTOR; ANABOLIC AGENT; ANDROGEN; ANDROSTENEDIONE; BETA ADRENERGIC RECEPTOR; CIMICIFUGA RACEMOSA EXTRACT; CLOMIFENE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOLLITROPIN RELEASING FACTOR; FREE RADICAL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOFLAVONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHYTOESTROGEN; PLANT EXTRACT; PRASTERONE SULFATE; PROGESTERONE; RALOXIFENE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RISEDRONIC ACID; SELECTIVE ESTROGEN ENZYME MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE; TIBOLONE; TOLTERODINE; UMBELLIFERA COMMUNIS EXTRACT; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; BLADDER INSTABILITY; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL TOXICITY; HEART PROTECTION; HORMONAL THERAPY; HORMONE ACTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LIVER TOXICITY; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; UMBELLULARIA; VAGINA BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

ANTIOXIDANTS; ESTROGENS; FEMALE; HUMANS; ISOFLAVONES; MENOPAUSE; OXIDATIVE STRESS;

EID: 20044369196     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054065819     Document Type: Review

References (125)

1. Barbo, DM. The physiology of the menopause. Med Clin North Am 1987; 71: 11-22.
2. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. Mechanisms of estrogen action. Physiol Rev 2001; 81: 1535-1565.
3. Davison S, Davis SR. Hormone replacement therapy: current controversy. Clin Endocrinol 2003; 58: 249-261.
4. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 1997; 59: 365-393.
5. Kelly MJ, Qiu J, Wagner EJ, Ronnekleiv OK. Rapid effect of estrogen on G-protein coupled receptor activation of potassium channels in the central nervous system (CNS). J Steroid Biochem Mol Biol 2002; 83: 187-193.
6. Bergamini CM, Pansini FS, Bettocchi S Jr, Segala V, Dallocchio F, Bagni B, et al. Hormonal sensitivity of adenylate cyclase in human endometrium: modulation by estradiol. J Steroid Biochem 1985; 22: 299-303.
7. Calkin AC, Sudhir K, Honisett S, Williams MR, Dawood T, Komesaroff PA. Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2. J Clin EndocrinolMetab 2002; 87: 5072-5075.
8. Belker SM, Zsarnovszky A. Estrogenic actions in the brain: estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 2001; 299: 408-414.
9. Hextall A. Oestrogens and lower urinary tract function. Maturitas 2000; 36: 83-92.
10. Wagner JD, Kaplan JR, Burkman RT. Reproductive hormones and cardiovascular disease mechanism of action and clinical implications. Obstet Gynecol Clin North Am 2002; 29: 475-493.
11. Riggs BL, Khosla S, Melton LJ Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302.
12. Fink G, Sumner BE, McQueen JK, Wilson H, Rosie R. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol 1998; 25: 764-775.
13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. for the Heart and Estrogen/progestin Replacement Study (HERS) ResearchGroup. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1988; 280: 605-613.
15. Collins P. Clinical cardiovascular studies of hormone replacement therapy. Am J Cardiol 2002; 90: 30F-34F.
16. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002; 89: 12E-17E.
17. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler. Thromb Vasc Biol 2002; 22: 201-210.
18. Schairer C. Progesterone receptors - animal models and cell signalling in breast cancer: Implications for breast cancer of inclusion of progestins in hormone replacement therapies. Breast Cancer Res 2002; 4: 244-248;
19. Eden J. Progestins and breast cancer. J Obstet Gynecol 2003; 188: 1123-1131.
20. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases carcinoma risk in Sweden. Cancer 2003; 97: 1387-1392.
21. Gavin NI, Thorp JM, Ohsfeldt RL. Determinants of hormone replacement therapy duration among postmenopausal women with intact uteri. Menopause 2001; 8: 377-383.
22. Goldfrank D, Haytoglu T, Frishman WH, Mohammad Z. Raloxifene, a new selective estrogen receptor modulator. J Clin Pharmacol 1999; 39 : 767-774.
23. Kauffman RF, Bensch WR, Roudebush RE, Cole HW, Bean JS, Phillips DL, et al. Hypocholesterolemic activity of raloxifene (LY 139481): pharmacological chracterization of a selective estrogen receptor modulator. J Pharmacol Exp Ther 1997; 280: 146-153.
24. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continue breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125-134.
25. Seeman E. Raloxifene. J Bone Miner Metab 2001; 19: 65-75.
26. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002; 298: 843-846.
27. Pasqualini JR, Ebert C, Chetrite GS. The SEEM: selective estrogen enzyme modulators in breast cancer. Gynecol Endocrinol 1999; 6: 1-8.
28. Chetrite GS, Pasqualini JR The selective estrogen enzyme modulator (SEEM) in breast cancer. J. Steroid Biochem Mol Biol 2001; 76: 95-104.
29. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001; 76: 231-238.
30. de Gooyer ME, Kleyn GT, Smits KC, Ederveen AG, Verheul HA, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001; 183: 55-62.
31. Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001; 4: 203-208.
32. Yue W, Wang JP, Hamilton CJ, Demer LM, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998; 58: 927-932.
33. Von Eckardstein A, Crook D, Elbers J, Ragoobir J, Ezeh B, Helmond F, et al. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin Endocrinol 2003; 58: 49-58.
34. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin EndocrinolMetab 2002; 87: 16-23.
35. Samman S, Lyons Wall PM, Chan GS, Smith SJ, Petocz P. The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in premenopausal women. Atherosclerosis 1999; 147: 277-283.
36. Tikkanen MJ, Wahala K, Ojala S, Vihma V, Adlercreutz H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci USA 1998; 95: 3106-3110.
37. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91: 6-11.
38. Ginsburg J, Prelevic GM. Lack of significant hormonal effects and controlled trials of phyto-oestrogens. Lancet 2000; 355: 163-164.
39. Lu LJ, Tice JA, Bellino FL. Phytoestrogens and healthy aging: gaps in knowledge. A workshop report. Menopause 2001; 8: 152-153.
40. Fitzpatrick LA. Soy isoflavones: hope or hype? Maturitas 2003; 44: S21-29.
41. Vigna GB, Donegà P, Zanca R, Barban A, Passaro A, Pansini F, et al. Simvastatin, transdermal patch, oral estrogen-progestogen preparation in early-postmenopausal hypercholes-terolemic women: a randomized, placebo-controlled clinical trial. Metabolism 2002; 51: 1463-1470.
42. Bell NH. Advances in the treatment of osteoporosis. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 93-102.
43. Bergamini CM, Gambetti S, Dondi A, Cervellati C. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 2004; 10: 1611-1626.
44. Mariotto S, Menegazzi M, Suzuki H. Biochemical aspects of nitric oxide. Curr Pharm Des 2004; 10: 1627-1645.
45. Subbiah MTR. Mechanisms of cardioprotection by estrogens. Proc Soc Exper Biol Med 1998; 217: 23-29.
46. Ayers S, Tang M, Subbiah MTR. Estradiol 17-β as an antioxidant distinct features when compared to other fat soluble antioxidants. J Lab Clin Med 1996; 128: 367-375.
47. Shwaery GT, Vita GA, Keaney JF Jr. Antioxidant protection of LDL by physiological concentrations of 17β-estradiol. Requirement for estradiol modification. Circulation 1997; 95: 1378-1385.
48. Koh K. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55: 714-726.
49. Falkeborn M, Lithell H, Persson I, Vessby B, Maessen T. Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial. Climacteric 2002; 5: 240-248.
50. Hernandez I, Delgado JL, Diaz J, Quesada T, Teruel MJ, Llanos MC, et al. 17β-estradiol prevents oxidative stress and decrease blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1599-R1605.
51. Montilla P, Tunez MC, Delgado MJ, Salcedo M. Hyperlipidemic nephropathy induced by adriamycin in ovariectomized rats: role of free radicals and effect of 17-beta-estradiol administration. Nephron 2000; 85: 65-70.
52. Tikkanen MJ, Vihma V, Hockerstedt A, Jauhiainen M, Helisten H, Kaamanen M. Lipophilic oestrogen derivatives contained in lipoprotein particles. Acta Physiol Scand 2002; 176: 117-121.
53. Sokoloff L. The metabolism of the central nervous system in vivo. In: Field J, Magoun HW, Hall WE. (Eds.) Handbook of Physiology-Neurophysiology 1960; Vol. 3, Americal Physiological Society, Washington D.C.
54. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001; 53: 135-159.
55. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998; 39: 1529-1542.
56. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 140: 256-261.
57. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996; 156: 2213-2217.
58. Gandy S. Estrogen and neurodegeneration. Neurochem Res 2003; 28: 1003-1008.
59. Belker SM, Zsarnovszky A. Estrogenic actions in the brain: estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 2001; 299: 408-414.
60. Ruiz-Larrea MB, Martin C, Martinez R, Navarro R, Lacort M, Miller NJ. Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids 2000; 105: 179-188.
61. Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, et al. Estrogen receptor α, not β, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Scie USA 2001; 98: 1952-1957.
62. Inestrosa NC, Marzolo MP, Bonnefont AB. Cellular and molecular basisof estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Mol Neurobiol 1998; 17: 73-86.
63. Loper-Jaramillo P, Teran E. Improvement in functions of the central nervous system by estrogen replacement therapy might be related with an increased nitric oxide production. Endothelium 1999; 6: 263-266.
64. Grady D, Rubin SM, Petitti DB, Fox CL, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
65. Barret-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Ann Rev Public Health 1998; 19: 55-72.
66. Grodstein F, Manson JE, Colditz GA, Willet WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-941.
67. Mendelson ME, Karas RH. The protective effect of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
68. Pansini F, Bonaccorsi G, Calisesi M, Campobasso C, Franzè GP, Gilli G, et al. Influence of spontaneous and surgical menopause on atherogenic metabolic risk. Maturitas 1993; 17: 181-190.
69. Pansini F, Albertazzi P, Bonaccorsi G, Zanotti L, Campobasso C, Vigna G, et al. Hormonal replacement therapy and lipids: is transdermal norethisterone acetate better than oral medroxyprogesterone acetate? Menopause 1994; 1: 119-123.
70. Herrington D, Reboussin D, Brosnihan K, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000; 343: 522-529.
71. Mendelsohn ME. Nongenomic, estrogen receptor-mediated activation of endothelial nitric oxide synthase. How does it work? What does it mean? Circ Res 2000; 87: 677-682.
72. Ho KJ, Liao JK. Nonnuclear actions of estrogen. Arterioscler. Thromb Vasc Biol 2002; 22: 1952-1961.
73. Gragasin FS, Xu Y, Arenas IA, Kainth N, Davidge ST. Estrogen reduces angiotensin II-induced nitric oxide sinthase and NAD(P)H oxidase expression in endothelial cells. Arteriosclerosis Thromb Vasc Biol 2003; 23: 38-44.
74. Leal M, Diaz J, Serrano E, Abellan J, Carbonell LF. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet Gynecol 2000; 95: 804-809.
75. Kim YD, Chen B, Beanregard J, Konretas P, Thomas G, Farhat MY, et al. 17-beta-estradiol prevents dysfunction of canine coronary endothelium and myocardial and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation 1996; 94: 2901-2908.
76. Walsh BA, Busch BL, Mullick, Reiser KM, Rutledge JC. 17 β-estradiol reduces glycoxidative damage in the artery wall. Arterioscler. Thromb Vasc Biol 1999; 19: 840-846.
77. Bhavnani BR, Cecutti A, Gerulath A, Woolever AC, Berco M. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause 2001; 8: 395-397.
78. Ruiz-Sanz JI, Navarro R, Martinez R, Martin C, Lacort M, Matorras R, et al. l7beta-estradiol affects in vivo the low density lipoprotein composition, particle size, and oxidizability. Free Radic Biol Med 2001; 31:391-397.
79. Subbiah MT, Abplanalp W. Evidence of increased formation of products retaining strong antioxidant activity from estradiol-17beta oxidation in the presence of human plasma lipoproteins. J Lab Clin Med 2002; 139: 357-363.
80. Arteaga E, Villaseca P, Rojas A, Arteaga A, Bianchi M. Comparison of the antioxidant effect of estriol and estradiol on low density lipoproteins in postmenopausal women. Rev Med Clin 1998; 126: 481-487.
81. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-288.
82. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
83. Shulman GI, Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
84. Duplus E, Glorian M, Forest V. Fatty acid regulation of gene transcription. J Biol Chem 2000; 275: 30749-30752.
85. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
86. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int 2000; 58: 26-30.
87. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production block three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
88. Paolisso G, Giugliano D. Oxidative stress and insulin action. Is there a relationship? Diabetologia 1996; 39: 357-363.
89. Wojtczak L, Schonfeld P. Effect of fatty acids on energy coupling processes in mithocondria. Biochim Biophys Acta 1993; 1183: 41-57.
90. Pansini F, Bonaccorsi G, Genovesi F, Folegatti MR, Bagni B, Bergamini CM, et al. Influence of estrogens on serum free fatty acids levels in women. J Clin EndocrinolMetab 1990; 71: 1387-1389.
91. Delmas P, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Eng J Med 1997; 337: 1641-1647.
92. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
93. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular seperoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
94. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K, et al. Raloxifene impreves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002; 105: 2083-2091.
95. Maccarone M, Lorenzon T, Guerieri P, Finazzi-Agrò A. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem 1999; 265: 27-34.
96. Appendino G, Spagliardi P, Cravotto G, Pocock V, Milligan S. Daucane phytoestrogens: a structure-activity study. J Nat Prod 2002; 65: 1612-1615.
97. Ikeda K, Arao Y, Otsuka H, Nomoto S, Horiguki H, Kato S, et al. Terpenoids found in the umbelliferae family act as agonists/antagonists for ERα and ERβ: differential transcription activity between ferutinine-liganded ERα and ERβ. Biochem Biophys Res Commun 2002; 291: 354-360.
98. http://www.cfsan.fda.gov/-lrd/fr000908.html, released October 26, 1999.
99. Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 2001; 8: 384-392.
100. Reinli K, Block G. Phytoestrogen content of foods - a compendium of literature values. Nutr Cancer 1996; 26: 123-48.
101. Adlercreutz H, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G, et al. Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 1986; 25: 791-797.
102. Reynolds RF, Walker AM, Obermeyer CM, Rahman O, Guilbert D. Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO. J Clin Epidemiol 2001; 54: 1056-1064.
103. Safe S, Connor K, Ramamoorthy K, Gaido K, Maness S. Human exposure to endocrine-active chemicals: hazard assessment problems. Regul Toxicol Pharmacol 1997; 26: 52-58.
104. Mazur W, Adlercretz H. Overview of naturally occurring endocrine-active substances in the human diet in relation to human health. Nutrition 2000; 16: 654-658.
105. Ju YH, Doerge DR, Allred KF, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002; 62: 2474-2477.
106. Jones JL, Daley BJ, Enderson BL, Zhou JR, Karlstad MD. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am Surg 2002; 68: 575-577.
107. Yellayi S, Zakroczymski MA, Selvaraj V, Valli VE, Ghanta V, Helferich WG, et al. The phytoestrogen genistein suppresses cell-mediated immunity in mice. J Endocrinol 2003; 176: 267-274.
108. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252-4263.
109. Foth D, Cline JM. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr 1998; 68: 1413S-1417S
110. Mackey R, Eden J. Phytoestrogens and the menopause. Climacteric 1998; 1: 302-308.
111. Adlercreutz H, Hamalainen E, Gorbach S, Goldin B. Dietary phyto-oestrogens and the menopause in Japan. Lancet 1992; 339: 1233.
112. Fotsis T, Pepper M, Montesano R, Aktas E, Breit S, Schweigerer L, et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin EndocrinolMetab 1998; 12: 649-666.
113. Kim MH. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem 2003; 89: 529-538.
114. Blum A, Lang N, Vigder F, Isreali P, Gumanovsky M, Lupovitz S, et al. Effects of soy protein on endothelium-dependent vasodilatation and lipid profile in postmenopausal women with mild hypercholesterolemia. Clin Investi Med 2003; 26: 20-25.
115. Boros LG, Bassilian S, Lim S, Lee WN. Genistein inhibits nonoxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. Pancreas 2001; 22: 1-7.
116. Fajardo I, Quesada AR, Nunez de Castro I, Sanchez-Medina F, Medina MA A comparative study of the effects of genistein and 2-methoxyestradiol on the proteolytic balance and tumour cell proliferation. Br J Cancer 1999; 80: 17-24.
117. Li B, Yu S. Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation. Biol Pharm Bull 2003; 26: 780-786.
118. Christiansen C. Osteoporosis: Diagnosis and Management Today and Tomorrow. Bone 1995; 5: 513S-516S.
119. Syed Z, Khan A. Bone densitometry: applications and limitations. J Obstet Gynaecol Can 2002; 24: 476-484.
120. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF and Erdman JW jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998; 68: 1375S-1379S.
121. Chen X, Garner SC, Quarles LD, Anderson JJ. Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J Nutr Biochem 2003; 14: 342-349.
122. Jenkins DJ, Kendall CW, Connelly PW, Jackson CJ, Parker T, Faulkner D, et al. Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. Metabolism 2002; 51: 919-924.
123. Bergamini CM, Gambetti S, Dondi A, Cervellati C. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Design 2004; 10(14): 1611-26.
124. Hertelendy F, Zakar T. Regulation of myometrial smooth muscle functions. Curr Pharm Design 2004; 10(20): 2499-517.
125. You L. Phytoestrogen genistein and its pharmacological interactions with synthetic endocrine-active compounds. Curr Pharm Design 2004; 10(22): 2749-57.